Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment guidelines news

Show

From To
HIV care is threatened by proposed changes to Medicare Part D

Optimal HIV care includes early and uninterrupted access to effective antiretroviral medications. Proposed changes to Medicare Part D threatens that.

Published
25 January 2019
From
STAT
What's New in the U.S. HIV Clinical Guidelines

We walk you through the most recent updates to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of HIV.

Published
21 December 2018
From
TheBody.com
How HIV Physicians Can Better Treat an Aging Population

A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.

Published
12 December 2018
From
Poz
Starting HIV treatment at diagnosis slashes drop out, drug failure rates, China study finds

Patients diagnosed with HIV who started antiretroviral treatment within 30 days had significantly lower rates of dropping out of treatment, and higher rates successful treatment, than those who started later, particularly those who started more than three months after their diagnosis, a study in China has found.

Published
04 June 2018
From
Science Speaks
HIV Care Gaps of Less Than 9 Months Do Not Worsen Patients

Gaps in care of up to 9 months for patients with HIV do not worsen viral loads, a study involving more than 6000 HIV-infected individuals has found. Current guidelines specify that gaps in visits to primary care doctors should not exceed 6 months for clinically stable HIV patients with sustained viral suppression—even though longer lapses are common.

Published
16 May 2018
From
MD Magazine
Computer Models Are Changing How We Craft HIV-AIDS Policies

A computer modeling of AIDS-affected populations of sub-Saharan Africa has recently enabled the World Health Organization (WHO) to identify a cost-effective measure to address the increasing prevalence of drug-resistant HIV in the region.

Published
04 May 2018
From
Healthcare Analytics News
India could shift from efavirenz to dolutegravir for HIV treatment – at no extra cost, new research suggests

Researchers recommend dolutegravir (DTG)‐based antiretrovirals should become the first option for HIV treatment in India, following a study into DTG’s cost-effectiveness.

Published
13 April 2018
From
Avert
U.S. Guidelines Panel Strongly Recommends Gilead’s HIV Regimen Biktarvy

The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.

Published
04 April 2018
From
Poz
Study finds more than half of patients worldwide don’t access HIV treatment until immune systems are severely compromised

Data from nearly a million patients starting treatment for HIV across the world over the last decade shows 55 percent of them accessed antiretroviral treatment only after their immune cell — or CD4 — counts had dropped below 200, leaving them extremely vulnerable to illnesses and infections.

Published
02 February 2018
From
Science Speaks
Chronic pain common in people living with HIV

HIVMA comprehensive guidelines recommend screening everyone with HIV, offering multidisciplinary treatment focusing on non-drug options.

Published
14 September 2017
From
EurekAlert
← First12345...10Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.